TD Cowen Boosts Danaher (NYSE:DHR) Price Target to $310.00

Danaher (NYSE:DHR) had its price target lifted by TD Cowen from $290.00 to $310.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the conglomerate’s stock.

Several other analysts also recently weighed in on the company. Robert W. Baird boosted their price target on Danaher from $259.00 to $271.00 and gave the company an outperform rating in a research note on Wednesday, April 24th. StockNews.com downgraded Danaher from a buy rating to a hold rating in a research note on Tuesday, June 25th. Evercore ISI lowered their target price on Danaher from $266.00 to $260.00 and set an outperform rating on the stock in a research note on Tuesday, July 2nd. Bank of America upped their target price on Danaher from $270.00 to $275.00 and gave the stock a neutral rating in a research note on Wednesday. Finally, HSBC upgraded Danaher from a hold rating to a buy rating and upped their target price for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $276.88.

Danaher Stock Up 1.4 %

Danaher stock opened at $273.91 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.43. The business’s 50-day simple moving average is $255.16 and its two-hundred day simple moving average is $249.22. The company has a market cap of $197.82 billion, a PE ratio of 46.43, a PEG ratio of 4.18 and a beta of 0.83. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $277.72.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.05 EPS. Equities analysts anticipate that Danaher will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, July 26th. Shareholders of record on Friday, June 28th were given a dividend of $0.27 per share. The ex-dividend date was Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold 84,775 shares of company stock valued at $21,802,690 over the last quarter. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Danaher

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC increased its holdings in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher in the second quarter valued at approximately $25,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $29,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher in the first quarter valued at approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.